Molnupiravir INN
Composition : Each Capsule Contains Molnupiravir INN 200mg.
Indication : It is indicated for the treatment of mild to
moderate coronavirus disease 2019 (COVID-19) in adults with a positive
SARS-COV-2 diagnostic test and who have at least one risk factor for developing
severe illness.
Dosage and administration: Adults:The recommended dose of Molnupiravir is 800 mg (four
200 mg capsules) taken orally every 12 hours for 5 days.The safety and efficacy
of Molnupiravir when administered for periods longer than 5 days have not been
established. Molnupiravir should be
administered as soon as possible after a diagnosis of COVID-19 has been made
and within 5 days of symptom onset.
Paediatric population: The safety and efficacy of Molnupiravir in patients
below 18 years of age have not been established. No data are available.
Or, as directed by the registered physician.
Use in pregnancy and lactation :
Pregnancy: There
are no data from the use of Molnupiravir in pregnant women. Studies in animals
have shown reproductive toxicity. Molnupiravir is not recommended during
pregnancy. Women of childbearing potential should use effective contraception
for the duration of treatment and for 4 days after the last dose of
Molnupiravir.
Breast-feeding: It is unknown whether Molnupiravir or
any of the components of molnupiravir are present in human milk, affect human
milk production, or have effect on the breastfed infant. Animal lactation
studies with molnupiravir have not been conducted.Based on the potential for
adverse reactions on the infant from Molnupiravir, breast-feeding is not
recommended during treatment and for 4 days after the last dose of
Molnupiravir.
Packing: Each box contains 40’s capsules in container.
